Background Heterozygous mutations in the CASK gene in Xp11.4 have been shown to be associated with a distinct brain malformation phenotype in females, including disproportionate pontine and cerebellar hypoplasia. Methods The study characterised the CASK alteration in 20 new female patients by molecular karyotyping, fluorescence in situ hybridisation, sequencing, reverse transcriptase (RT) and/or quantitative real-time PCR. Clinical and brain imaging data of a total of 25 patients were reviewed.
INTRODUCTION
In 2008, we identified heterozygous loss-of-function mutations in the X-linked CASK gene, including disruption of the gene by a paracentric X-chromosomal inversion, submicroscopic deletions, and sequence changes in four female patients with severe intellectual disability (ID), postnatal microcephaly, and pontocerebellar hypoplasia (MICPCH; MIM 300749). We also described a partly penetrant CASK splice mutation in a severely affected male patient who died at the age of 2 weeks, and hypothesised that hypomorphic CASK alleles could be compatible with life in males. 1 Two reports on female patients with heterozygous de novo deletions of w3.2 and w4.0 Mb covering part of CASK provided further evidence for CASK as a gene for an X-linked form of microcephaly and severe ID manifesting mainly in females. 2 3 Very recently, loss-of-function mutations of CASK have been reported in 10 females with MICPCH. 4 CASK is a calcium/calmodulin dependent serine protein kinase and belongs to the membrane associated guanylate kinase (MAGUK) protein family. 5 Although expressed in different tissues, CASK is widely distributed in different regions of the brain. 6 The CASK protein interacts with about 18 different binding partners and plays a critical role in brain development and synaptic function. It is important in: (1) presynaptic organisation and regulation of neurotransmitter release; (2) maintaining the morphology of dendritic spines and regulating ion channels at the postsynaptic site; and (3) regulating the expression of genes involved in cortical development, such as RELN and GRIN2B, by entering the nucleus of neurons. 7 8 Since the first description, CASK mutations have also been described in males with a milder phenotype comprising variable ID, nystagmus, and microcephaly. 9e11 Preliminary data suggest that the severe brain malformation phenotype is caused by CASK null alleles, whereas the milder phenotype is due to hypomorphic missense mutations. However, data on both groups are limited so far due to the small number of patients.
Since 2008, we ascertained 20 novel female patients with severe ID, microcephaly, and pontine and cerebellar hypoplasia, and characterised all of them. Here we summarise the clinical, brain imaging, and molecular data of novel and previously published CASK mutation positive patients to define better the associated phenotypic spectrum. 
METHODS Patients
We obtained clinical data, brain imaging studies and results of laboratory testing, as well as blood or DNA samples, from 20 patients with ID, microcephaly, and pontocerebellar hypoplasia, who were assessed by experienced clinical geneticists and/or neurologists. Two patients were recruited through the MRNET consortium (http://www.german-mrnet.de). High resolution molecular karyotyping was performed on a clinical basis for eight female patients using different array platforms (detailed information is available on request). All available brain imaging studies from these 20 patients and from five female patients with a CASK mutation published previously 1 2 were reviewed by two of the authors (GU and WBD). Clinical data and facial phenotypes were reviewed by UM and GU. The clinical data and samples were obtained with informed consent, including consent to use the photographs in this report, under protocols approved by Institutional Review Boards at all participating institutions.
Fluorescence in situ hybridisation
Fluorescence in situ hybridisation (FISH) experiments were performed to confirm molecular karyotyping data. Metaphase spreads from peripheral blood lymphocytes were prepared by standard procedure. Bacterial artificial chromosomes (BACs) (RP11 human BAC library), P-1 derived artificial chromosomes (PACs) (RPCI human PAC libraries 1 and 5), and fosmid clones (WIBR-2 human fosmid library [G248P8]) were received from the BACPAC Resource Center, Children's Hospital Oakland, California, USA. The BAC clone CTD-3115N12 (CalTech human BAC library) was obtained from Invitrogen, Karlsruhe, Germany. BAC, PAC, and fosmid DNA was prepared using the NucleoBond Xtra Midi kit (Macherey-Nagel, Düren, Germany). DNA was labelled by nick translation using the CGH Nick Translation Kit and Spectrum Green-dUTP (Vysis, Downers Grove, Illinois, USA) according to the protocol provided. Chromosomes were counterstained using 4',6-diamidino-2-phenylindole (DAPI) (Serva Feinbiochemica, Heidelberg, Germany) and mounted in antifading solution (Vector Labs, Burlingame, California, USA). Slides were analysed with a Leica Axioscope fluorescence microscope. Images were merged using a cooled CCD camera (Pieper, Schwerte, Germany) and CytoVision software (Applied Imaging, San Jose, California, USA).
Sequencing of CASK
The coding region of the CASK gene (27 exons; GenBank accession no. NM_003688) was amplified from genomic DNA. Primer sequences are available on request. Amplicons were directly sequenced using the ABI BigDye Terminator Sequencing Kit (Applied Biosystems, Darmstadt, Germany) and an automated capillary sequencer (ABI3130; Applied Biosystems). Sequence electropherograms were analysed using Sequence Pilot software (JSI medical systems, Kippenheim, Germany). Where mutations were shown to have arisen de novo, we verified relationships by genotyping both parents and the patient at 10 microsatellite loci.
CASK transcript analysis
A fresh venous blood sample (2.5 ml) of patient 8 was collected into a PAXgene Blood RNA Tube (PreAnalytiX; Qiagen, Hilden, Germany). Total RNA was extracted by use of the PAXgene Blood RNA Kit (Qiagen) according to the manufacturer 's instructions; 1 mg of RNA was reverse transcribed into cDNA (Superscript II; Invitrogen, Karlsruhe, Germany) using random hexanucleotides (Invitrogen) according to the manufacturer's protocol. Reverse transcriptase PCR (RT-PCR) fragments were obtained by the use of forward primer CASK-ex1F (5 9 -GTTTT CGAAGCCCTCCACGCTGCG-3 9 ) and reverse primer CASKex4R (5 9 -GCTTCACTGTACACAAAACCAGC-3 9 ) according to standard PCR protocols. PCR products were cloned into pCR2.1 TOPO TA Cloning Vector (Invitrogen). Escherichia coli clones were subjected to colony PCR and PCR products from individual clones were sequenced.
CASK copy number analysis
Real time quantitative PCR on genomic DNA was carried out using Rotor Gene RG-3000 (Qiagen) in 100 ml tubes (72-well rotor) with a final reaction of 20 ml. All reactions were prepared with 10 ml of 2x SYBR Green JumpStart Taq ReadyMix (SigmaAldrich, Taufkirchen, Germany) and 400 nM forward and reverse primers. Primers for real time experiments were designed using the web based 'qPCR Primer & Probe Design' tool provided by MWG-Eurofins (ecom.mwgdna.com) and primer sequences are available on request. The exon 4 of the CFTR gene was used as an internal reference. A total of 30 ng of DNA was used as template for each sample that was analysed in duplicate. Thermal cycling conditions included a pre-run of 5 min at 958C. Cycle conditions were 40 cycles at 958C for 30 s, 588C for 30 s, and 728C for 45 s. Relative quantification of exon copy numbers on genomic DNA was carried out using the comparative threshold cycle (ddCt) method: the starting copy number of exons in patients was determined in comparison with the known copy number of the calibrator sample (healthy male control), using the following formula: ddCt ¼ [dCt CASK (CASK patient) À dCt CFTR (CASK patient) À (dCt CASK (healthy male) À dCt CFTR (healthy male))]. The relative exon copy number was calculated by the expression 2^-(ddCt 6 SE)dthat is, of about 2 for a diploid sample (female) and about 1 for a haploid sample (male).
X chromosome inactivation assay
Quantitative examination of the methylation pattern at the AR locus was performed as previously described. 12 
Computational analyses
Splice site prediction of one intronic variant identified in CASK was calculated by using the online tools SpliceView, the Berkeley Drosophila Genome Project (BDGP) (http://www.fruitfly.org/26), and the NetGene2 server (http://www.cbs.dtu.dk/services/ NetGene2/).
RESULTS
The results of molecular and brain imaging studies, and clinical data of the 20 new cases with CASK mutations, are summarised in table 1.
Molecular results

Identification of deletions and duplications covering CASK by molecular karyotyping
High resolution molecular karyotyping was performed on a clinical basis on eight female patients with microcephaly and severe developmental delay (DD) or ID. We identified submicroscopic deletions covering (parts of) CASK in six patients and duplications in two (figure 1). The smallest deletion was identified in patient 24. She carried a de novo w60 kb deletion including CASK exons 6e8, confirmed by FISH with fosmids (table 1) . In patient 8, two sequence variationsdthe splice mutation c.173-2A>C in intron 2 and the missense mutation c.174T>A (p.D58E) in exon 3dwere identified (table 1) . Both sequence changes destroy a BglII restriction site. By subsequent restriction of the genomic PCR product harbouring exon 3 and adjacent intronic sequences with BglII we obtained two restricted fragments (from the wild-type allele) and an unrestricted fragment (from the mutant allele; data not shown). These data indicate that both point mutations occurred on the same allele and are likely the result of a small rearrangement on one CASK allele of patient 8. In silico analysis using the splice site prediction programs 'Splice View', 'NetGene2', and 'Berkeley Drosophila Genome Project' revealed that the c.173-2A>C mutation disrupts the splice acceptor site and most probably results in altered splicing (data not shown). Next, we analysed CASK transcripts by generating an RT-PCR product with primers located in exons 1 and 4 and obtained an amplicon with the expected size of 409 bp in patient 8 ( figure 3A) . A second PCR product of w300 bp was only observed in the patient and not in control individuals ( figure 3A ). Subcloning and direct sequencing of both amplicons of patient 8 demonstrated correct splicing of exon 2 to exon 3 in the 409 bp amplicon (data not shown), while exon 2 was spliced to exon 4 in the 303 bp amplicon ( figure 3B ). Skipping of exon 3 leads to a frameshift in the CASK mRNA. In this scenario, the missense mutation c.174T>A (p.D58E) in exon 3 on the same allele has no pathogenic relevance. Five of the nine CASK alterations were de novo, while the parents of patients 16 and 28e30 were not available.
Copy number analysis of CASK by FISH and real-time quantitative PCR
By CASK sequence analysis, we did not identify a mutation in patients 18, 20, and 26. To detect a possible microdeletion of CASK in these patients, serial FISH analyses with BAC, PAC, and fosmid clones covering the complete gene were performed (figure 1). BAC clone CTD-3115N12 yielded only one signal on metaphase spreads of patient 18, similar to the five fosmid clones G248P82722E4, G248P80319B6, G248P82570C9, G248P80427H9, and G248P80557B1 (figure 1 and data not shown). Thus, patient 18 was shown to have a w120 kb microdeletion covering at least CASK exons 6e12. Neither of her parents carried the deletion (data not shown). In patients 20 and 26, no deletion could be detected by FISH. Next, we used realtime PCR for comparative quantification of copy numbers of selected CASK exons, intron 1, and a DNA region upstream of CASK on genomic DNA of the two patients. The relative copy number of CASK exons 7 and 8 in patient 20 and of amplicons surrounding CASK exon 1 in patient 26 was comparable to a haploid sample (figure 2). The de novo deletion of w100 kb in patient 26 was confirmed by FISH with fosmids G248P86259A10 and G248P80448B4 ( figure 1 and data not shown) . From the DNA of patient 20, we amplified a 376 bp breakpoint-spanning PCR product (data not shown). Direct sequencing revealed an 11 218 bp deletion comprising 3351 bp of CASK intron 6, exon 7 (176 bp), intron 7 (4715 bp), exon 8 (123 bp), and 2853 bp of intron 8 ( figure 3C ). At the junction, a 5 bp overlap (AGATC) was detected (figure 3C). We identified Alu repeats next to the breakpoint (data not shown) suggesting non-allelic homologous recombination (NAHR) as the likely mechanism for the rearrangement in patient 20. The junction fragment could not be amplified from the DNA of patient 20's parents, indicating de novo occurrence (data not shown). We confirmed all parental identities where mutations had arisen de novo. 
X chromosome inactivation analysis
Brain imaging studies
Brain imaging studies (MRI in 23 individuals and CT in patient 9) and clinical data (see below) were reviewed in a total of 25 CASK mutation positive individuals, including the 20 novel patients described here and five published patients (patients 1e4 in Najm et al 1 and case 4 in Froyen et al, 2 numbered as patient 9 in figure 4 ). Brain imaging consistently showed pontocerebellar hypoplasia with a dilated fourth ventricle, but of remarkably varying degrees (figure 4). The cerebral cortex presented with simplified gyration (mildly reduced number and complexity of gyri) in the frontal region in eight of 22 cases, whereas in 14 of 22 cases providing sufficient information, the cerebrum appeared normal with mild dilatation of the lateral ventricles in a few cases. The corpus callosum was intact with normal appearance in all cases (22/22). The pons was moderately to severely flattened in one of 23 cases, appeared mildly or subtly (very mildly) hypoplastic in 15 of 23 and six of 23 cases, respectively, and was normal in the remaining one of 23. The cerebellar hypoplasia affected the vermis and cerebellar hemispheres proportionally. Of the 24 cases, the cerebellum was mildly hypoplastic in 10 cases, moderately hypoplastic in 11, and severely hypoplastic in three cases. The fourth ventricle was enlarged in 18 of 23 cases and the size appeared normal in five of 23 cases. In at least two cases this was due to the small size of the posterior fossa with verticalisation of the tentorium. In one patient an arteriovenous malformation was observed (patient 30). In patient 22, original scans were not available but brainstem and cerebellar hypoplasia was present by report of CT imaging. No other brain anomalies were identified.
Clinical data
Clinical data of a total of 25 female patients could be studied (20 individuals reported here, patients 1e4 in Najm et al 1 and case 4 in Froyen et al 2 ). All patients were female, aged between 10 months and 21 years at last follow-up, with a mean age of 6 years 2 months. With the exception of two individuals (patient 15 in this study and patient 3 in Najm et al 1 ), all showed severe psychomotor retardation or ID, depending on their age. The majority never attained the ability to walk: only four out of 21 patients of at least 1 year of age learnt to walk without support at ages ranging from 18 months to 4½ years.
Patient 15 could speak two-word sentences at the age of 4 years, but all other patients had no speech or produced vowels, syllables or <10 words. Fourteen out of 22 patients showed general or axial hypotonia, whereas 10 of 22 exhibited general or peripheral hypertonia, sometimes progressing to spasticity. Movement disorders were seen infrequently (patients 16, 22, 26, 30), and one patient showed mild bulbar involvement (patient 19). Eight patients suffered from seizures of various types with onset at 1 to 8 years.
Eight out of 23 patients had sensorineural hearing loss. Nineteen out of 24 patients exhibited various ophthalmologic anomalies with optic nerve hypoplasia (5/19) or optic disc pallor (4/19), and strabismus (5/19) being the most common ones; two girls had a colobomatous defect.
All patients had significant microcephaly (occipitofrontal circumference (OFC) #3.4 SD, up to À10 SD) which was of prenatal or, most commonly, of early postnatal origin and evident in all cases during the first year of life. At birth, nine newborns showed an OFC of less than À2 SD, the OFC of six babies corresponded to À2 SD, and the birth OFC of the other 10 babies was still within the normal range. Fifteen out of 24 patients also showed postnatal growth retardation of varying degree, whereas birth length had been in the normal range for all of them. Other congenital anomalies (fusion of kidneys, mitral valve incompetence, pectus excavatum, hypoplastic toenails) were only seen in a minority of patients, with no particular anomaly occurring recurrently.
The facial phenotype of 23 patients could be studied. Apart from microcephaly, the following features were noticed: upslanting palpebral fissures (2), hypertelorism or telecanthus (4), hypotelorism (1), epicanthus (4), broad nasal bridge (14), prominent nasal bridge (6), broad or bulbous nasal tip (8), small 
DISCUSSION
We present molecular data of 20 new female patients and clinical data of a total of 25 female individuals with a CASK alteration. The mutations most likely lead to a CASK null allele: 11 submicroscopic copy number alterations, including nine deletions of w11 kb to 4.5 Mb and two duplications, all covering (part of) CASK, four splice mutations, four nonsense mutations, one missense mutation, and one 1 bp deletion. The intragenic duplication comprising exons 2e8 could interfere with splicing and lead to aberrant CASK transcripts, as demonstrated for the 0.2 Mb intragenic duplication in patient 9 described by Hayashi et al. 4 If the duplicated fragment of the second duplication containing at least exons 1e13 was inserted in reverse orientation within the CASK gene, the integrity of the gene could be disturbed resulting in a CASK null allele. We could not establish a correlation between the genotype and specific clinical features or the degree of brain anomalies. In particular, the phenotype of patients with larger deletions including multiple genes other than CASK was indistinguishable from that caused by mutations only affecting CASK. Likewise, Hayashi et al found similar phenotypes of ID with MICPCH caused by different CASK loss-of-function mutations, including two deletions of 1.1 and 3.0 Mb. 4 The XCI pattern was random or slightly skewed in the majority (14/15) of females. The only two patients with a highly skewed XCI (patient 15 and case 4 in Froyen et al 2 ) harboured a larger deletion in Xp11.3p11.4. Remarkably, patient 15 with the largest deletion comprising CASK seems to have the mildest clinical manifestation, which may be explained by highly skewed XCI. Skewed XCI can result from a cell selection process downstream of X inactivation. 13 We hypothesise that pronounced skewing of XCI in the two patients with a large Xp11.3p11.4 deletion can be attributed to loss of other genes in the deleted interval, while loss of CASK itself has no deleterious effect on proliferation and/or cell division of leucocytes as demonstrated by random XCI in all patients with an intragenic CASK mutation (table 1) .
The 25 patients clinically studied had a remarkably similar phenotype. Brain imaging consistently demonstrated diffuse brainstem and cerebellar hypoplasia of a remarkably varying degree, proportionally affecting the vermis and cerebellar hemispheres. . Apart from microcephaly, a prominent and/or broad nasal bridge and tip, a small chin and large ears were noticed in the majority of patients. In some cases, the nose was short or small, and the philtrum long (photographs submitted with written consent from the patients' legal guardians for publication in print and online).
The cerebral cortex showed simplified gyration in the frontal region in some cases, whereas it appeared normal in the majority of patients, with mild dilatation of the lateral ventricles in some of them. The corpus callosum (CC) was normal in all cases. These data corroborate the recent finding by Takanashi et al that a normal CC together with a low cerebrum/CC ratio may be an imaging clue to specifically recognise females with a CASK mutation.
14 Moreover, these findings significantly help in distinguishing CASK related diffuse brainstem and cerebellar hypoplasia from other disorders. The proportionate involvement of cerebellar vermis and hemispheres in most girls with CASK mutations may differentiate them from children with pontocerebellar hypoplasia types 2 and 4 (PCH2 and PCH4), which have disproportionate involvement. The latter consists of flat cerebellar hemispheres and small but less severely affected vermis that give a dragonfly-like appearance to the cerebellum. 15 16 In only a few females with CASK alterations are the cerebellar hemispheres more severely affected than the vermisdfor example, in patient 29. These findings are in line with a recent paper on de novo CASK mutations in three females; one was reported to have a dragonfly-like pattern of PCH and two had a proportionate hypoplasia of cerebellar hemispheres and vermis.
17 PCH2 and PCH4 are caused by mutations in three different genes, namely TSEN54, TSEN34, and TSEN2. 15 Clinically, PCH2 is characterised by progressive microcephaly, failure of motor development, central visual impairment, and dystonia or dyskinesia. In PCH type 4, which was previously known as olivopontocerebellar hypoplasia, an earlier prenatal onset with C-shaped inferior olives and often early postnatal demise is seen. 16 In particular, movement disorders may distinguish PCH2 from the CASK associated phenotype as they are less common in patients with a CASK mutation. In addition, spasticity shortly after birth and epilepsy may lead to the diagnosis of PCH2, 16 18 since spasticity develops later and seizures are not very frequent in patients with CASK mutation (eight of 25 cases), while the presence of sensorineural hearing loss may prompt CASK testing.
The core clinical phenotype in patients with a CASK mutation studied here consisted of severe DD/ID, mild and variable congenital microcephaly, and severe postnatal microcephaly (OFC À3.5 to À10 SD) by 1 year of age, often associated with postnatal growth retardation, and (axial) hypotonia with or without hypertonia of extremities, possibly progressing to spasticity. Optic nerve hypoplasia and/or other eye abnormalities, and sensorineural hearing loss were found in some cases. By evaluating clinical photographs of females with a CASK alteration, a recognisable facial phenotype emerged, including prominent and/or broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears.
The severe and distinct brain malformation phenotype in females caused by loss-of-function mutations in CASK is different from the milder phenotype caused by hypomorphic CASK alleles described so far. The CASK sequence change c.83G>T (p.R28L) was found in three males of an Italian family with clinical findings suggestive of FG syndrome (ID, relative macrocephaly, congenital hypotonia, constipation, and behavioural anomalies) and a normal MRI. Two carrier females were unaffected. 10 This mutation leads to partial skipping of exon 2 and results in an out-of-frame CASK transcript. 10 Additional sequence alterations of CASK have been reported in male patients from six families with mild to severe ID, with or without congenital nystagmus, microcephaly, and/or dysmorphic facial features: five missense mutations (p.Y268H, p.P396S, p.D710G, p.W919R, p.Y728C) and the splice mutation c.2521-2A>T resulting in an in-frame deletion of several amino acids in CASK. 9 11 Carrier females in these families were unaffected or mildly affected showing nystagmus, tremor and/or mild ID. Only some of the affected males had undergone brain imaging, which showed cerebellar hypoplasia and pachygyria in one of them; further information was not available. 9 Together, these data suggest that highly deleterious mutations in CASK in the heterozygous state are consistently associated with a severe phenotype in females, while hypomorphic point mutations cause a milder phenotype, including X-linked nystagmus and variable ID, particularly in males. In these cases, the CASK protein may still fulfil some functions.
In summary, we describe a very consistent phenotype in females with a CASK null allele, comprising diffuse brainstem and cerebellar hypoplasia of variable degree with normal appearing corpus callosum, severe microcephaly of prenatal or early postnatal origin, severe ID, and possibly sensorineural hearing loss. Developmental features, brain malformations, and the emerging facial phenotype should allow clinical recognition of appropriate girls and females with severe ID and prompt genetic testing of CASK.
